Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence

Abstract Background The development of Bruton’s tyrosine kinase inhibitors (BTKi) for the treatment of chronic lymphocytic leukaemia (CLL) has provided a highly effective and relatively non-toxic alternative to conventional chemotherapy. Some studies have shown that BTKi can also lead to improvement...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Joanne E. Davis, Chia Sharpe, Kylie Mason, Constantine S. Tam, Rachel M. Koldej, David S. Ritchie
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
R
Acceso en línea:https://doaj.org/article/72b9726b70ce4860bc6b28377c17d44e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!